XML 57 R41.htm IDEA: XBRL DOCUMENT
v3.25.4

STOCK-BASED COMPENSATION (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract] |
Schedule of non-cash compensation expense related to equity awards | Non-cash compensation related to equity awards is included in the following line items in the accompanying consolidated statements of operations and comprehensive income (loss) (in thousands):
| Year Ended December 31,
| 2025 |  | 2024 |  | 2023
Cost of revenue | $ | 173 |  |  | $ | 297 |  |  | $ | 396 |
Selling and marketing expense | 2,637 |  |  | 3,303 |  |  | 5,267 |
General and administrative expense | 23,672 |  |  | 20,478 |  |  | 25,180 |
Product development | 2,720 |  |  | 4,501 |  |  | 6,333 |
Restructuring and severance | 255 |  |  | — |  |  | 2,506 |
Total non-cash compensation | $ | 29,457 |  |  | $ | 28,579 |  |  | $ | 39,682 |
Summary of changes in outstanding stock options | A summary of changes in outstanding stock options is as follows:
| Number of Options |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value(a)
|  |  | (per option) |  | (in years) |  | (in thousands)
Outstanding at December 31, 2024 | 371,386 |  |  | $ | 226.17 |  |  |  |  |
Granted | — |  |  | — |  |  |  |  |
Exercised | — |  |  | — |  |  |  |  |
Forfeited | — |  |  | — |  |  |  |  |
Expired | (11,909) |  |  | 144.89 |  |  |  |  |
Outstanding at December 31, 2025 | 359,477 |  |  | $ | 228.86 |  |  | 2.51 |  | $ | — |
Options exercisable | 359,477 |  |  | $ | 228.86 |  |  | 2.51 |  | $ | — |
(a)The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company's closing stock price of $53.09 on the last trading day of 2025 and the exercise price, multiplied by the number of shares covered by in-the-money options) that would have been received by the option holder had the option holder exercised these options on December 31, 2025. The intrinsic value changes based on the market value of the Company's common stock. A summary of changes in outstanding stock options with market conditions at target is as follows:
| Number of Options with Market Conditions |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value(a)
|  |  | (per option) |  | (in years) |  | (in thousands)
Outstanding at December 31, 2024 | 699,312 |  |  | $ | 227.74 |  |  |  |  |
Granted | — |  |  | — |  |  |  |  |
Exercised | — |  |  | — |  |  |  |  |
Forfeited | — |  |  | — |  |  |  |  |
Expired | (217,643) |  |  | 300.00 |  |  |  |  |
Outstanding at December 31, 2025 | 481,669 |  |  | $ | 195.10 |  |  | 0.78 |  | $ | — |
Options exercisable | 481,669 |  |  | $ | 195.10 |  |  | 0.78 |  | $ | — |
(a)The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company's closing stock price of $53.09 on the last trading day of 2025 and the exercise price, multiplied by the number of shares covered by in-the-money options) that would have been received by the option holder had the option holder exercised these options on December 31, 2025. The intrinsic value changes based on the market value of the Company's common stock.
Schedule of changes in outstanding non-vested RSUs, restricted stock and RSUs with performance conditions | A summary of changes in outstanding nonvested RSUs is as follows:
| RSUs
| Number of Units |  | Weighted Average Grant Date Fair Value
|  |  | (per unit)
Nonvested at December 31, 2024 | 569,460 |  |  | $ | 46.37 |
Granted (a) | 561,615 |  |  | 42.31 |
Vested | (369,294) |  |  | 50.21 |
Forfeited | (41,321) |  |  | 41.29 |
Nonvested at December 31, 2025 | 720,460 |  |  | $ | 41.50 |
(a)The grant date fair value per share of the RSUs is calculated as the closing market price of LendingTree's common stock at the time of grant. A summary of changes in outstanding nonvested RSUs with market conditions is as follows:
| RSUs with Market Conditions (a) |  |
| Number of Units |  | Weighted Average Grant Date Fair Value |  |  |  |
|  |  | (per unit) |  |  |  |
Nonvested at December 31, 2024 | 46,000 |  |  | $ | 35.24 |  |  |  |  |
Granted | 145,000 |  |  | 36.46 |  |  |  |  |
Vested | (60,527) |  |  | 35.66 |  |  |  |  |
Forfeited | (51,473) |  |  | 33.34 |  |  |  |  |
Nonvested at December 31, 2025 | 79,000 |  |  | $ | 38.39 |  |  |  |  |
(a)During the year ended December 31, 2025, the Company granted RSUs with market conditions that will vest if the Company's 90 trading day average closing stock prices equals or exceeds certain price hurdles ($60.00, $75.00 and $90.00) during the performance period of March 10, 2025 to March 10, 2029, and granted RSUs with market conditions that will vest if the Company's 90 trading day average closing stock prices equals or exceeds certain price hurdles ($75.00 and $90.00) during the performance period of December 31, 2025 to December 31, 2028. Upon achievement of each price hurdle, one-half of the awards will vest upon the later of the achievement date or the one-year anniversary of the grant date, and the other half of the awards will vest on the first anniversary of the achievement date.
Schedule of RSUs with market conditions valuation assumptions | For purposes of determining stock-based compensation expense, the weighted average grant date fair value per share of the RSUs with market conditions was estimated using the Monte Carlo simulation model, which requires the use of various key assumptions.
| Year Ended December 31,
| 2025 | 2024
Expected term (1) | 3.00 - 4.00 years | 5.00 years
Expected volatility (2) | 74.09% - 75.11% | 68.06 | %
Risk-free interest rate (3) | 3.52% - 3.91% | 4.13 | %
Expected dividend (4) | — |  | — |
(1)The expected term of RSUs with market conditions granted was calculated using the respective performance period plus any time-based vesting requirement. (2)The expected volatility rate is based on the historical volatility of the Company's common stock. (3)The risk-free interest rate is specific to the date of grant. The risk-free interest rate is based on U.S. Treasury yields for notes with comparable expected terms as the awards in effect at the grant date. (4)For all RSUs with market conditions granted, no dividends are expected to be paid over the contractual term of the stock options, resulting in a zero expected dividend rate.
Schedule of employee stock purchase plan valuation assumptions | For purposes of determining stock-based compensation expense, the grant date fair value per share estimated using the Black-Scholes option pricing model required the use of the following key assumptions:
| Year Ended December 31,
| 2025 | 2024 | 2023
Expected term (1) | 0.50 years | 0.50 years | 0.50 years
Expected dividend (2) | — |  | — |  | — |
Expected volatility (3) | 71% - 79% | 78% - 82% | 82%
Risk-free interest rate (4) | 4.24% - 4.29% | 5.28% - 5.33% | 4.76% - 5.50%
(1)The expected term was calculated using the time period between the grant date and the purchase date. (2)No dividends are expected to be paid, resulting in a zero expected dividend rate. (3)The expected volatility rate is based on the historical volatility of the Company's common stock. (4)The risk-free interest rate is specific to the date of grant. The risk-free interest rate is based on U.S. Treasury yields for notes with comparable expected terms as the Employee Stock Purchase Rights, in effect at the grant date.

X
- Definition Schedule Of Share-Based Payment Award, Excluding Stock Options, Valuation Assumptions + References No definition available. + Details
Name: | tree_ScheduleOfShareBasedPaymentAwardExcludingStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | tree_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 50 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718-50/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration